KLK3 and prostate carcinoma: Between 27% and 53% of all patients with prostate cancer (PCa) undergoing radical prostatectomy (RP) or radiation therapy (RT) develop a biochemical recurrence (BCR) defined as rising prostate-specific antigen (PSA) serum levels after curative treatment for PCa [1].